OakChart

Calidi Biotherapeutics Inc

CLDIHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 8:37 AM ET

0.7650+0.0810 (11.84%)
2026-11-11 14:44 CET
Market cap
2.51 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-23.45 USD m
Free cash flow, TTM
-17.84 USD m
EPS diluted, TTM
-54.07
P/E
-
Compare

Price

CLDI against its 20, 50 and 200-day averages
2050200earnings
0.0010.0020.001.7M3.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CLDIclose 0.7720-day 0.7250-day 0.97200-day 3.880.77

97.2% under 27.04 on 6 Nov 2025. Last 15 sessions, 27.7% high to low

Profile

CLDI
52-week range, 1% of the way up
0.6224.96

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

Employees29
IPONov 01, 2021
Beta1.35
ATR, 14d0.08
Rel volume0.27
Short float3.73%
Insider own0.87%
Inst own1.83%

Snapshot

6 groups

Valuation

Index-
Market Cap2.81M
Enterprise Value0.46M
Income-23.45M
Sales0.00M
Book/sh1.50
Cash/sh1.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPONov 01, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.51
P/C0.65
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.68
Current Ratio1.68
Debt/Eq0.62
LT Debt/Eq0.25
Option/ShortNo / Yes

Earnings

EPS (ttm)-54.07
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y74.50% -
Sales past 3/5Y- -
EPS Y/Y TTM53.95%
Sales Y/Y TTM-
EPS Q/Q90.76%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own0.87%
Insider Trans0.00%
Inst Own1.83%
Inst Trans-3.25%
ROA-283.36%
ROE-957.93%
ROIC-601.56%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.38%
SMA50-21.21%
SMA200-80.30%
Trades-

Technical

Shs Outstand3.68M
Shs Float3.64M
Short Float3.73%
Short Ratio1.16
Short Interest0.14M
52W High24.96 -96.94%
52W Low0.62 23.39%
Volatility12.95% 10.56%
ATR (14)0.08
RSI (14)46.22
Beta1.35
Rel Volume0.27
Avg Volume116.92K
Volume1,590

Performance

Perf Week4.80%
Perf Month-14.99%
Perf Quarter-50.32%
Perf Half Y-76.09%
Perf YTD-95.91%
Perf Year-96.70%
Perf 3Y-99.98%
Perf 5Y-100.00%
Perf 10Y-
Recom1.00
Target Price1920.00
Prev Close0.68
Price0.76
Change %11.84%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Nov 22, 2023InitiatedHH.C. WainwrightBuy$11+1,337.9%
Oct 09, 2023InitiatedRRobert W. BairdOutperform$9+1,076.5%

Peers

Mkt cap
TickerCompanyMkt cap
GNLXGenelux Corp88.23M
TOVXTheriva Biologics Inc7.11M
ONCYOncolytics Biotech Inc48.64M
CADLCandel Therapeutics Inc723.10M
REPLReplimune Group Inc2.24B
IMNNImunon Inc4.32M
GOVXGeovax Labs Inc1.36M
GNPXGenprex Inc1.76M
AIMAIM ImmunoTech Inc5.96M
INDPIndaptus Therapeutics Inc460.75M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Camaisa AllanDirectorDec 12 '25Sale1.468501,23776,952Dec 16 07:37 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.61B

News

latest 14 of 206
  • Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories (GlobeNewswire)
  • Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026 (GlobeNewswire) -6.40%
  • Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency (GlobeNewswire) -5.83% -5.31%
  • Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering (GlobeNewswire) +8.55%
  • Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Loading…
  • Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -5.52%
  • Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference (GlobeNewswire) +9.50%
  • Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers (GlobeNewswire) -13.93%
  • Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 (GlobeNewswire)
  • Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire) +5.35%
  • Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit (GlobeNewswire)
  • Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors (GlobeNewswire)
  • Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-2.940--34.5600.00--
2026Q12026-05-14-6.880--6.8560.00--
2025Q42026-03-27-9.120--8.9920.00--
2025Q32025-11-13---2.210---
2025Q22025-08-08-31.840-30.720-31.7840.00-1
2025Q12025-05-14-34.560-28.800-35.3430.00-1
2024Q42025-03-31-51.840-71.040-37.8910.00-2
2024Q32024-11-12-124.8-164.26-12.4030.00-2
2024Q22024-08-13-268.8-278.4-268.030.00-2
2024Q12024-05-14-384-528-390.180.000.002
2023Q42024-03-15-441.6-393.6-444.790.000.002
2023Q32023-11-14-268.8-326.4-271.570.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-3,322-2,688-3,3220.000.00
2024FY-570.24-709.44-571.18--
2025FY-95.200--570.24--
2026FY--88.320---
2027FY--76.800---
2028FY--74.880---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYR2025-10-28100-88.32-88.32-88.32
2026FYR2025-10-27100-88.32-88.32-88.32
2026FYR2025-10-26100-88.32-88.32-88.32
2026FYR2025-10-25100-88.32-88.32-88.32
2026FYR2025-10-24100-88.32-88.32-88.32
2026FYR2025-10-23100-88.32-88.32-88.32
2026FYR2025-10-22100-88.32-88.32-88.32
2026FYR2025-10-21100-88.32-88.32-88.32
2026FYR2025-10-20100-88.32-88.32-88.32
2026FYR2025-10-19100-88.32-88.32-88.32
2026FYR2025-10-18100-88.32-88.32-88.32
2026FYR2025-10-17100-88.32-88.32-88.32
2026FYR2025-10-16100-88.32-88.32-88.32
2026FYR2025-10-15100-88.32-88.32-88.32

Estimate history

EPS, annual226.176-5740.128-3321.773-571.179-95.133-54.0728
Period20212022202320242025TTM
EPS, quarterly-268.032-12.403-37.891-35.343-31.784-35.287-8.992-6.856-2.938
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.0450000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0150.0040.0190.1080.4512.083
Period20212022202320242025MRQ
Shares, quarterly0.0340.4850.1080.1660.180.4320.4510.7372.083
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.040.00
Cost of Goods Sold Incl. D&A1.711.651.531.260.270.00
Gross Profit-1.71-1.65-1.53-1.26-0.230.00
Selling, General and Administrative Excl. Other16.1418.5920.2427.7422.901.78
Research and Development9.869.748.8813.017.26-
Other Operating Expense0.000.000.000.000.000.00
Operating Income-17.85-20.24-21.78-28.99-23.13-1.78
Interest Expense0.160.210.933.750.160.00
Unusual Expense-0.03-0.00-0.32-0.712.12-5.17
Net Income Before Taxes-17.49-20.05-22.20-29.20-25.423.39
Income Taxes0.020.010.010.020.010.00
Consolidated Net Income-23.49-25.74-22.21-29.22-25.433.39
Net Income From Continuing Operations-23.45-25.58-22.14-29.22-25.433.39
Net Income-23.45-25.58-23.81-29.22-25.433.39
EPS (Recurring)-16.58-95.14-576.62-3,378.04-5,404.33-15.36
EPS (Basic, Before Extraordinaries)-54.07-95.13-571.18-3,321.77-5,740.13226.18
EPS (Diluted)-54.07-95.13-571.18-3,321.77-5,740.13226.18
EBITDA-16.14-18.59-20.24-27.74-22.87-1.78
Non-Operating Income (Expense)0.480.400.192.83-0.010.00
Other After Tax Adjustments-5.98-5.670.000.000.000.00
Stock Option Compensation Expense1.131.672.343.803.57-
Price To Earnings Ratio----27.9727.97
Price To Sales Ratio----1,922.13-
Gross Margin-----508.89-
Operating Margin-----51,395.56-
Net Margin-----56,504.44-
Shares Outstanding2.080.450.110.020.000.01
Market Capitalization2.512.5123.8753.51292.39292.39

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.440.430.420.430.410.390.390.39
Gross Profit-0.44-0.43-0.42-0.43-0.41-0.39-0.39-0.39
Selling, General and Administrative Excl. Other3.713.764.044.625.264.673.634.84
Research and Development2.562.592.362.362.592.421.812.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.15-4.19-4.47-5.05-5.66-5.06-4.03-5.23
Interest Expense0.040.040.040.040.050.070.170.23
Unusual Expense0.00-0.05-0.090.100.02-0.04-0.05-0.38
Net Income Before Taxes-4.16-4.10-4.06-5.17-5.76-5.06-4.14-5.07
Income Taxes0.010.00-0.000.010.000.000.00-0.00
Consolidated Net Income-4.16-4.42-4.06-10.85-5.76-5.06-4.15-5.07
Net Income From Continuing Operations-4.16-4.42-4.06-10.82-5.71-4.99-4.10-5.05
Net Income-4.16-4.42-4.06-10.82-5.71-4.99-4.10-5.05
EPS (Recurring)-2.94-6.91-9.13-35.06-31.71-35.52-38.20-13.06
EPS (Basic, Before Extraordinaries)-2.94-6.86-8.99-35.29-31.78-35.34-37.89-12.40
EPS (Diluted)-2.94-6.86-8.99-35.29-31.78-35.34-37.89-12.40
EBITDA-3.71-3.76-4.04-4.62-5.26-4.67-3.63-4.84
Non-Operating Income (Expense)0.030.070.360.02-0.020.040.010.01
Other After Tax Adjustments0.00-0.310.00-5.670.000.000.000.00
Stock Option Compensation Expense0.120.230.360.420.410.480.490.55
Shares Outstanding2.080.740.450.430.180.170.110.48
Market Capitalization2.512.818.4410.507.9418.0023.87106.14

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments5.709.692.050.471.06
Short Term Receivables0.000.001.360.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.560.540.890.310.42
Total Current Assets6.2610.234.300.791.48
Net Property, Plant & Equipment2.463.805.341.090.00
Total Investments and Advances0.120.130.230.00230.00
Intangible Assets---0.000.00
Other Assets0.020.020.140.720.28
Total Assets8.8614.1810.022.60231.77
Short Term Debt Incl. Current Port. of LT Debt1.524.451.925.540.00
Accounts Payable0.612.072.882.270.06
Other Current Liabilities1.812.985.4335.180.35
Total Current Liabilities3.949.5010.2342.990.41
Long Term Debt1.052.595.310.450.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.120.132.710.0016.04
Total Liabilities5.1012.2118.2543.4416.45
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.009.600.00
Common Equity3.761.53-8.23-50.44215.32
Total Shareholders Equity3.761.53-8.23-40.84215.32
Accumulated Minority Interest0.000.430.000.000.00
Total Equity3.761.97-8.23-40.84215.32
Total Liabilities & Stockholders Equity8.8614.1810.022.60231.77
Book Value Per Share8.3314.19-445.11-11,282.3814,379.50
Tangible Book Value Per Share8.3314.19-445.11-11,282.3814,379.50
Full-Time Employees2928412-
Price to Book Ratio0.4515.56-48.919.209.20
Return on Assets-222.05-182.99-110.51-21.70-
Return on Equity-966.52--201.40-29.15-
Return on Invested Capital-532.12-536.93--1.57
Quick Ratio1.591.080.420.023.61
Current Ratio1.591.080.420.023.61

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-17.51-20.06-22.21-29.22-25.433.39
Depreciation1.711.651.531.260.25-
Other Funds (Non Cash)1.091.862.687.228.39-4.18
Funds from Operations-14.70-16.55-18.00-20.74-16.78-0.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.05-4.74-1.70-6.243.57-0.29
Cash from Operating Activities-17.75-21.29-19.69-26.98-13.21-1.08
Capital Expenditures-0.09-0.12-0.02-0.58-0.430.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.002.000.000.000.00
Purchase or Sale of Investments-0.05-0.050.000.000.00-230.00
Purchase of Investments-0.05-0.050.000.000.00-230.00
Sale Or Maturity of Investments0.000.000.00-190.010.00
Other Uses0.000.000.000.00-0.070.00
Other Sources0.000.000.000.110.000.00
Cash from Investing Activities-0.14-0.171.98-0.48-0.49-230.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock18.0820.8025.0130.3010.76232.79
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock18.0820.8025.0130.3010.76232.79
Proceedsfrom Stock Options18.0720.7920.2030.0210.65227.69
Issuance or Reduction of Debt, Net-1.13-3.251.910.901.380.00
Change in Long Term Debt-1.13-3.251.710.901.380.00
Issuance of Long Term Debt0.000.003.593.251.500.00
Reduction of Long Term Debt-1.13-3.25-1.88-2.35-0.120.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.64
Other Financing Activities Uses0.000.000.000.000.00-0.64
Cash from Financing Activities16.8117.4625.3629.0412.09232.15
Exchange Rate Effect-0.000.01-0.01-0.01-0.03-
Net Change in Cash-1.09-3.997.641.58-1.651.06
Free Cash Flow-17.84-21.41-19.71-27.57-13.64-1.08
Preferred Dividends (Cash Flow)-0.00-0.000.000.00
Price to Free Cash Flow----2,430.89-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.296.735.7010.475.3810.66
Short Term Receivables0.270.000.000.000.050.05
Inventories0.000.000.000.000.000.00
Other Current Assets0.870.620.560.550.620.78
Total Current Assets5.437.356.2611.036.0511.49
Net Property, Plant & Equipment1.772.102.462.863.263.43
Total Investments and Advances0.000.120.120.340.100.12
Other Assets0.010.020.02-0.20-0.060.02
Total Assets7.209.598.8614.039.3515.06
Short Term Debt Incl. Current Port. of LT Debt1.181.501.521.872.192.45
Accounts Payable0.930.900.611.151.231.21
Other Current Liabilities1.131.431.812.171.931.77
Total Current Liabilities3.243.843.945.195.355.43
Long Term Debt0.770.751.051.441.822.25
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.070.070.120.200.100.09
Total Liabilities4.074.665.106.837.287.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3.134.933.766.921.766.94
Total Shareholders Equity3.134.933.766.921.766.94
Accumulated Minority Interest0.000.000.000.280.310.36
Total Equity3.134.933.767.202.087.30
Total Liabilities & Stockholders Equity7.209.598.8614.039.3515.06
Book Value Per Share1.506.708.3316.039.8141.92
Tangible Book Value Per Share1.506.708.3316.039.8141.92
Full-Time Employees--29---
Price to Book Ratio0.450.572.251.524.502.59
Return on Assets-283.36-202.88-222.05-247.70-251.58-177.17
Return on Equity-957.93-421.19-966.52---
Return on Invested Capital-106.69-77.65-84.38-129.53-159.50-54.24
Quick Ratio1.681.921.592.121.132.12
Current Ratio1.681.921.592.121.132.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.16-4.11-4.06-5.18-5.76-5.06
Depreciation0.440.430.420.430.410.39
Other Funds (Non Cash)0.160.180.120.630.540.57
Funds from Operations-3.56-3.50-3.52-4.12-4.81-4.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.79-0.62-1.53-0.11-0.07-3.04
Cash from Operating Activities-4.35-4.12-5.04-4.24-4.88-7.13
Capital Expenditures-0.03-0.01-0.03-0.03-0.06-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00-0.050.000.000.00
Purchase of Investments0.000.00-0.050.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.01-0.08-0.03-0.06-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.995.370.4910.230.0010.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.995.370.4910.230.0010.08
Proceedsfrom Stock Options1.995.370.4910.230.0010.08
Issuance or Reduction of Debt, Net-0.24-0.04-0.12-0.72-0.74-1.67
Change in Long Term Debt-0.24-0.04-0.12-0.72-0.74-1.67
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.24-0.04-0.12-0.72-0.74-1.67
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.835.160.349.48-0.478.11
Exchange Rate Effect-0.00-0.010.010.000.010.00
Net Change in Cash-2.561.03-4.785.21-5.400.97
Free Cash Flow-4.39-4.12-5.07-4.26-4.94-7.14

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.73%0.1M3.6M140.61K
2026-10-154.51%0.2M3.6M251.00K
2026-09-306.41%0.2M3.6M269.30K
2026-09-158.90%0.2M2.6M269.36K
2026-08-319.03%0.2M2.6M312.51K
2026-08-1412.24%0.3M2.6M324.60K
2026-07-3121.42%0.2M1.1M315.19K
2026-07-1519.71%0.2M1.1M379.02K
2026-06-3024.63%0.3M1.1M366.09K
2026-06-157.01%0.1M1.1M302.95K
2026-05-294.29%0.0M1.1M261.57K
2026-05-153.87%0.0M1.1M241.50K
2026-04-3031.07%0.2M0.6M219.70K
2026-04-152.81%0.0M0.6M28.28K
2026-03-313.00%0.0M0.5M14.92K
2026-03-133.39%0.0M0.3M11.45K
2026-02-271.09%0.0M0.3M4.79K
2026-02-131.95%0.0M0.3M5.35K
2026-01-306.67%0.0M0.2M7.76K
2026-01-152.03%0.0M0.3M8.18K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-258-KCurrent report2026-09-21SEC
2026-09-228-KCurrent report2026-09-17SEC
2026-09-17424B5SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-318-KCurrent report2026-07-27SEC
2026-07-168-KCurrent report2026-07-10SEC
2026-06-293Initial statement of beneficial ownership of securities2026-06-17SEC
2026-06-238-KCurrent report2026-06-17SEC
2026-06-188-KCurrent report2026-06-12SEC
2026-06-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-298-KCurrent report2026-05-28SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-088-KCurrent report2026-05-06SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-29SEC
2026-04-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-17SEC
2026-04-028-KCurrent report2026-03-29SEC
2026-03-31SCHEDULE 13DSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12001.24K1
2025-110000

Institutional holders

Manager% owned
UBS Group AG1.48%
GEODE CAPITAL MANAGEMENT, LLC1.36%
StoneX Group Inc.0.44%
HighTower Advisors, LLC0.43%
JANE STREET GROUP, LLC0.28%
Independent Advisor Alliance0.23%
RS CRUM INC.0.22%
Arax Advisory Partners0.19%
Private Advisor Group, LLC0.16%
VANGUARD CAPITAL MANAGEMENT LLC0.13%

Funds

Fund% owned
Fidelity Extended Market Index Fund1.33%
VANGUARD EXTENDED MARKET INDEX FUND0.13%
Fidelity Total Market Index Fund0.01%
Fidelity Series Total Market Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CLDI. Cached 15 minutes.